Drug Treatments. Abstract. History. Uses of Respiratory Medicine
|
|
- Louise Higgins
- 8 years ago
- Views:
Transcription
1 SLEEP APNEA / Drug Treatments 59 airway pressure increases nasal airway resistance. American Journal of Respiratory and Critical Care Medicine 154: Sin DD, Mayers I, Man GC, and Pawluk L (2002) Long-term compliance rates to continuous positive airway pressure in obstructive sleep apnea: a population-based study. Chest 121: Wiest GH, Harsch IA, Fuchs FS, et al. (2002) Initiation of CPAP therapy for OSA: does prophylactic humidification during CPAP pressure titration improve initial patient acceptance and comfort. Respiration 69: Young T, Palta M, Dempsey J, et al. (1993) The occurrence of sleep-disordered breathing among middle-aged adults. New England Journal of Medicine 328: Pathophysiology of SDB Airway collapse Symptoms of SDB Treatment options Nasal steroids Modafenil Drug Treatments D Auckley, Case Western Reserve University, Cleveland, OH, USA & 2006 Elsevier Ltd. All rights reserved. Abstract The conventional first-line treatments available for sleep apnea (continuous positive airway pressure therapy, oral appliances, and surgical intervention) are appropriate for people with symptomatic disease. The benefit of a drug treatment approach is one of convenience and ability to intervene at an earlier stage of the disease, or an alternative for those who cannot or will not accept or tolerate surgical or mechanical treatments. However, drug therapy at present is an uncertain option for the management of sleep apnea. Medications for sleep apnea can broadly be divided into the following functional categories: those that alter the upper airway neuromechanical properties, those that affect the control of respiration, and those that work as adjunctive therapy to minimize symptoms. Some drugs are known to act through more than one discrete pathway. While most attempts at drug therapy for sleep apnea have generally been unsuccessful, certain medications may have some use in specific clinical settings. In summary, convincing data for drug treatment as primary therapy is lacking, and additional therapy with one of the conventional sleep apnea treatments is often still the better option. Recent interest has focused on serotonin active agents as a treatment for obstructive sleep apnea. However, this class of medications is not yet approved for this indication. History Sleep apnea has been recognized as a significant clinical disorder for only the last three decades. As data accumulates linking multiple adverse outcomes to obstructive sleep apnea (OSA), the importance of treating this condition has become widely accepted. Likewise, central sleep apnea (CSA) is associated with worse outcomes in those with impaired cardiac function. Conventional therapies for sleep apnea include the use of pneumatic airway splints (continuous positive airway pressure (CPAP) devices), oral appliances to enlarge the upper airway, and surgery Abnormal control of breathing to either modify the airway, help facilitate ventilatory support, and/or to bypass the site of obstruction altogether (tracheotomy). While these therapies can be very successful for controlling or eliminating sleep apnea, each is hampered by limitations that impact their effectiveness in clinical practice. CPAP is problematic from a patient compliance standpoint. Oral appliances are effective in only a subset of patients with OSA and are also limited by suboptimal patient compliance. Surgical interventions can be highly effective in the right setting, but are generally restricted to OSA patients with surgically amenable anatomy who are willing to accept the risk of complications and the possibility of unacceptable long-term consequences. Thus, the use of a pill to treat sleep apnea seems highly desirable and remains a field of intense study. This article will review the current state of medical therapy for sleep apnea (Figure 1). Uses of Respiratory Medicine Thyroid hormone MPA Theophylline Acetazolamide Figure 1 Pathophysiology of and treatment options for sleep disordered breathing (SDB). If any agent is used as monotherapy for sleep apnea, then repeat objective testing is recommended (with the exception of modafinil). * Treatment options for OSA; w treatment options for CSA; MPA, medroxyprogesterone. Medications Affecting Airway Neuromechanical Properties Serotonin active agents Upper airway dilator muscle activity decreases during sleep, narrowing the airway. In the presence of abnormal pharyngeal anatomy, this results in repetitive airway collapse during sleep, or OSA. The neurotransmitter serotonin (also known as 5-HT) plays an integral role in maintaining patency of the upper airway by
2 60 SLEEP APNEA / Drug Treatments activating upper airway dilator muscles. As such, investigators have reasoned that increasing central serotonin levels may improve airway patency and eliminate OSA. Unfortunately, the physiology is not this simple as at least 14 different serotonin receptor subtypes have been identified and some of these, when stimulated, exhibit inhibitory effects on upper airway motor tone. This may in part explain why human trials of selective serotonin reuptake inhibitors (SSRIs) have failed to show a clinical benefit in OSA patients. It is likely that mixed serotonin receptor agonist antagonists are needed to produce clinically significant changes. Preliminary work with mirtazapine, a 5-HT 1 receptor agonist and 5-HT 2 and 5-HT 3 receptor antagonist, has shown promise in animal models of sleep apnea. Trials are underway to assess its effectiveness in humans with sleep apnea. It is hoped that ongoing work with serotonin and serotonin receptors will lead to better-targeted therapies. While this area holds great promise, serotonin active agents as monotherapy for OSA cannot be recommended at this time. Protriptyline Protriptyline is a nonsedating tricyclic antidepressant with REM sleep-suppressing properties. Like serotonin, protriptyline also stimulates the hypoglossal motor neurons to increase upper airway muscle activity. A number of investigators have studied protriptyline as a potential therapy for OSA. In sum, these studies have not shown clinically significant improvements in OSA (two studies found statistically significant reductions in the apnea hypopnea index (AHI), though moderate to severe OSA persisted). In addition, the high frequency of intolerable anticholinergic side effects limits protriptyline s clinical utility. Protriptyline should not be considered as a treatment option for OSA at this time. Topical nasal steroids Nasal airflow resistance may contribute significantly to the development of OSA. Available data suggests that sleep apnea is more common in individuals with chronic nasal congestion as compared to those without. Initial studies suggested that treatment of chronic nasal congestion with nasal steroids improved sleep, reduced daytime fatigue, and decreased sleepiness, though measures of sleep apnea were not specifically addressed. Only one placebo-controlled study has examined the impact of nasal steroids on parameters of OSA in adults with concomitant allergic rhinitis. This small study (23 patients total) showed an improvement in the AHI in treated patients, though the individual response to treatment was highly variable. The group on the whole decreased their AHI from 20 to 12 events per h, whereas the 13 patients entering the study meeting criteria for OSA (AHI X 5, the remainder considered to be primary snorers) only reduced their AHI from 30 to 23. Of the five individuals who decreased their AHI to o5, considered an optimal response, three had an AHI between 5 and 10 on placebo. These data suggest that in patients with mild OSA and allergic rhinitis, nasal steroid therapy may have a role, but for more severe disease, additional conventional therapy will probably be required. Medications Generally Affecting the Control of Breathing Hormonal therapy Both estrogen and progesterone have been studied as potential therapies for OSA. Medroxyprogesterone (MPA) is a recognized ventilatory stimulant, though it may exert some stimulatory effects on the upper airway motor neurons as well. By attenuating hypoventilation, MPA was hoped to reduce periodic breathing and improve sleep apnea. An early small, uncontrolled study found that MPA improved OSA in a subset of patients with baseline hypercapnia. Two subsequent placebo-controlled trials failed to show a treatment effect of MPA on OSA, though only four of the patients were known to be hypercapnic. Until larger randomized controlled trials of hypercapnic OSA patients are performed, MPA cannot routinely be recommended as a treatment option. Its role in treating patients with OSA and obesity hypoventilation syndrome is uncertain. An empiric trial could be considered in some individuals, provided objective follow-up testing is obtained. MPA has not been studied as a treatment for CSA. Estrogen has effects on upper airway musculature in addition to possible centrally mediated effects on respiration. Growing evidence suggests that the incidence of OSA in postmenopausal women increases and approaches that of age-matched men. It is of interest that in postmenopausal women on hormone replacement therapy (HRT), the incidence of OSA remains low. Despite these findings, no large randomized controlled trials of HRT in postmenopausal women with OSA have been reported to date. Two small (5 and 6 patients) nonrandomized, uncontrolled trials found significant improvements in the AHI following therapy with estrogen alone, though only one of the 11 subjects had normalization of their AHI. In contrast, another uncontrolled study of 15 postmenopausal women with moderate to severe OSA found little change in their AHI following treatment with estrogen. As might be expected from these findings, the majority of participants in all the studies did not perceive much subjective benefit in their sleep or daytime symptoms. Further study is
3 SLEEP APNEA / Drug Treatments 61 needed before HRT can be recommended in postmenopausal women for the treatment of OSA. Theophylline Theophylline is a methylxanthine that inhibits adenosine, a central-acting ventilatory depressant, as well as enhances the ventilatory response to hypoxia and hypercapnia. Thus, it might be expected that theophylline may improve CSA more than OSA. In two blinded placebo-controlled studies it was found that theophylline significantly improved central apneas with the most pronounced effect seen in the setting of left ventricular dysfunction (central apneas decreased from 26 to 6 h 1 on average in 15 subjects studied). However, sleep remained poor in these individuals due to theophyllineinduced sleep fragmentation. OSA, on the other hand, failed to improve following therapeutic range dosing of theophylline in a number of controlled trials. Two studies comparing theophylline to CPAP therapy have found CPAP to be considerably more efficacious. Before considering theophylline for patients with left ventricular dysfunction and central sleep apnea, one must consider the narrow therapeutic window and potential toxic side effects of theophylline. In addition, the sleep disruption this medication induces may lead to persistence of sleeprelated symptoms and, consequently, poor compliance with therapy. Acetazolamide Acetazolamide, a carbonic anhydrase inhibitor, produces a metabolic acidosis and thus stimulates respiration. This drug has been examined as a treatment for both central and obstructive sleep apnea. Uncontrolled data from a small number of subjects suggests acetazolamide may dramatically reduce the number of central events (mean central AHI decreased from 54 to 12 and 26 to 7 in two different studies) in sleep as well as improve associated daytime symptoms. No randomized controlled trial has been performed to confirm these findings. With regard to OSA, both uncontrolled studies and a single randomized placebo-controlled trial suggest that the AHI variably improves following treatment; however, significant OSA generally persists. Side effects, including intolerable parasthesias and severe metabolic acidosis, can occur when acetazolamide is given at higher doses and may restrict its clinical utility. At present, acetazolamide can be considered for patients with CSA, though close clinical monitoring is warranted. Thyroid replacement Hypothyroidism depresses the ventilatory drive, can impair upper airway muscle function due to myopathy, and may narrow the upper airway secondary to mucopolysaccharide deposition. Reversing these changes might be expected to improve sleep apnea in those found to be hypothyroid. Numerous small case series addressing this have yielded conflicting results as some show dramatic decreases in the AHI with thyroid replacement therapy and others show no effect. It is unclear if those failing to respond to irreversible functional or anatomic changes due to hypothyroidism or that other factors contributing to OSA risk (such as obesity or craniofacial abnormalities) may be playing a role. No randomized controlled trials addressing thyroid replacement in hypothyroid patients with OSA have been reported at this time. Based upon available data, it may be reasonable to utilize thyroid replacement as monotherapy for hypothyroid patients with mild OSA, but adjunctive conventional treatments should be considered for more severe OSA patients. All patients should undergo repeat evaluation of their sleep apnea once euthyroid status is achieved. Opioid antagonist The cerebral spinal fluid of individuals with OSA contains increased opioid levels that fall following successful treatment of the OSA. Through generalized cortical stimulation, opioid antagonists are thought to stimulate respiration. Controlled trials of continuous infusions of opioid antagonists (naloxone and doxapram) showed minor improvements in several parameters of OSA (oxygen saturation, length of apneas), though by and large these changes were of marginal clinical significance. Furthermore, these agents disturb sleep and require dosing via intravenous infusion, both undesirable qualities. Nicotine Nicotine stimulates respiratory drive by acting on central respiratory neurons. One uncontrolled trial found a decrease in the number of apneas in the first 2 h of sleep after subjects with OSA chewed nicotine gum at bedtime. However, a subsequent placebo-controlled study of transdermal nicotine found no significant improvement in the AHI or snoring intensity in a population of individuals with OSA and/or primary snoring. Nicotine was also noted to worsen sleep quality and induce intolerable gastrointestinal side effects in a number of study subjects. Benzodiazepines Benzodiazepines are not routinely recommended for patients with OSA due to concerns about depressing the arousal response, altering respiratory drive, and worsening airway collapse. It is of interest that a randomized placebo-controlled trial of the benzodiazepine receptor antagonist flumazenil found no benefit in patients with OSA, suggesting
4 62 SLEEP APNEA / Drug Treatments endogenous benzodiazepine receptor activation does not play a role in the pathophysiology of OSA. In contrast to concerns about decreased respiratory drive, some benzodiazepines have been shown to increase respiratory drive during sleep and therefore might improve CSA. The use of diazepam in a rat model of CSA found this to be the case. In humans, one small randomized placebo-controlled cross-over study of triazolam in idiopathic CSA demonstrated a reduction in the central apnea index and number of arousals with triazolam. Similar findings were noted in case series of subjects with periodic limb movements and CSA. Further study of benzodiazepines in CSA is warranted to clarify the specific patient populations who might stand to benefit from this therapy. Medications that Minimize Symptoms Despite optimal treatment of OSA, daytime sleepiness may not completely resolve. The reason for this is not clear, but the persistence of these symptoms can adversely impact quality of life and potentially increase the risk of accidents. Therefore, therapies to further reduce daytime symptoms of OSA in those already on conventional treatment have been studied. Modafinil Modafinil is a central-acting wake-promoting agent that has no effect on respiratory events in sleep. It has now been examined in two relatively large randomized placebo-controlled trials of OSA patients with persistence of daytime symptoms despite adequate treatment with CPAP. These studies showed consistent improvements in both subjective and objective measures of sleepiness as well as improvements in tests of vigilance and measures of quality of life. A clinically insignificant decrease in CPAP usage occurred during one of the trials, though this remains a concern when one considers the use of stimulants outside of a clinical trial setting. Based upon the available data, modafinil can be considered as an adjunct to conventional therapies for patients with residual OSA-related daytime sleepiness, though close monitoring of CPAP usage is encouraged. Other stimulants have not been tested in this setting. Etanercept Serum tumor necrosis factor alpha (TNF-a) and interleukin-6 (IL-6) are elevated in individuals with OSA, and have been proposed as mediators of the excessive daytime sleepiness that accompanies OSA. Etanercept neutralizes TNF-a and thus was tested in a small placebo-controlled pilot study of patients with OSA to assess its effects on OSA and OSA-related symptoms. While having a marginal impact on the AHI (decreased from 53 to 44, statistically significant but not clinically significant), a substantial improvement in an objective measure of sleepiness was seen. No subjective ratings of sleepiness or other quality of life measures were reported. Further study of this medication as an adjunctive therapy for persistent daytime symptoms in CPAP-treated OSA is warranted. Modification of Sleep Apnea by Other Treatments Antihypertensive agents While attempting to determine the best antihypertensive agents for patients with OSA, investigators noted that the AHI decreased modestly following treatment with betablockers or ACE inhibitors. Changing sympathetic tone or baroreceptor activity were the proposed mechanisms for these changes. These findings then led to two randomized trials of antihypertensive agents (beta-blockers, ACE inhibitors, calcium channel blockers, and diuretics) as treatments for OSA. Placebos were not included in either study. While all agents reduced blood pressure, the impact on OSA was marginal at best. One study showed a decrease in the AHI (from 40 to 27, clinically insignificant) while the other found no change in pre- and posttreatment measures. In the study reporting subjective symptoms, no improvement was noted. Clonidine, a rapid eye movement (REM)-suppressing agent, has also been evaluated as a treatment for OSA. One small placebo-controlled trial found no improvement in the AHI or symptoms following treatment with clonidine. Collectively, these data suggest that antihypertensive agents should not be utilized as therapy for the treatment of OSA. Glutamate antagonist Attenuating the respiratory response to acute hypoxia could prevent the periodic breathing pattern that may precipitate sleep apnea in some individuals. Glutamate, a neurotransmitter that may be partly responsible for hypoxia-induced respiratory stimulation, seems a reasonable target to antagonize and hopefully improve sleep apnea. One small randomized placebo-controlled trial of sabeluzole, a glutamate antagonist, documented an improved oxygen desaturation index during sleep, but did not measure the AHI specifically. On the other hand, baclofen, a glutamate antagonist and GABA agonist, did not decrease the AHI in 10 patients with mild OSA in a randomized placebo-controlled trial. Larger controlled trials of pure glutamate antagonists seem to be indicated. See also: Sleep Apnea: Overview; Adult; Continuous Positive Airway Pressure Therapy; Oral Appliances; Surgery for Sleep Apnea. Sleep Disorders: Central Apnea (Ondine s Curse); Upper Airway Resistance Syndrome.
5 SLEEP APNEA / Genetics of Sleep Apnea 63 Further Reading Hudgel DW and Thanakitcharu S (1998) Pharmacologic treatment of sleep-disordered breathing. American Journal of Respiratory and Critical Care Medicine 158: Javaheri ST, Parker J, Wexler L, et al. (1996) Effect of theophylline on sleep-disordered breathing in heart failure. New England Journal of Medicine 335: Kiely JL, Nolan P, and McNicholas WT (2004) Intranasal corticosteroid therapy for obstructive sleep apnoea in patients with co-existing rhinitis. Thorax 59(1): Kingshott RN, Vennelle M, Coleman EL, et al. (2001) Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. American Journal of Respiratory and Critical Care Medicine 163: Magalang UJ and Mador MJ (2003) Behavioral and pharmacologic therapy of obstructive sleep apnea. Clinics in Chest Medicine 24: Pack AI, Black JE, Schwartz JRL, and Matheson JK (2001) Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. American Journal of Respiratory and Critical Care Medicine 164: Smith I, Lasserson T, and Wright J (2003) Drug treatments for obstructive sleep apnoea. Cochrane Database of Systematic Reviews 2001(4), article CD Smith IE and Quinnell TG (2004) Pharmacotherapies for obstructive sleep apnoea: where are we now? Drugs 64(13): Veasey SC (2003) Serotonin agonists and antagonists in obstructive sleep apnea: therapeutic potential. American Journal of Respiratory Medicine 2(1): Vgontzas AN, Zoumakis E, Lin HM, et al. (2004) Marked decrease in sleepiness in patients with sleep apnea by Etanercept, a tumor necrosis factor-alpha antagonist. Journal of Clinical Endocrinology and Metabolism 89(9): Yap WS and Fleetham JA (2001) Central sleep apnea and hypoventilation syndrome. Current Treatment Options in Neurology 3: Genetics of Sleep Apnea S R Patel, Brigham and Women s Hospital at Harvard Medical School, Boston, MA, USA S Redline, Case Western Reserve University, Cleveland, OH, USA & 2006 Elsevier Ltd. All rights reserved. Abstract Obstructive sleep apnea is a disorder that has a clear genetic component. A familial basis for the disorder is evidenced by the substantially increased risk for snoring or sleep apnea among relatives of affected individuals. Approximately one-third of the population variance in apnea severity, as measured by the apnea/hypopnea index, is explained by familial clustering. The pathways by which genetic predisposition may influence the development of sleep apnea are multiple. Obesity, craniofacial anatomy, and ventilatory control are all traits that are highly heritable, and each influences the risk of apnea development. The genetics of obesity has been most well studied, with dozens of candidate genes proposed to influence a person s weight. Data suggest that these obesity-defining loci explain only half of the genetic variance in sleep apnea. Thus, other mechanisms are also important. Work is under way to identify risk genes for sleep apnea, and several candidates such as APOE have emerged. Research has also begun to identify genetic loci that may modulate the physiologic effect of sleep apnea on the development of secondary disorders, such as sleepiness, hypertension, and cardiac disease. Since a report in 1978 of three brothers with obstructive sleep apnea (OSA), it has become increasingly clear that this disease clusters within families. This suggests that genetic susceptibility plays an important role in apnea pathogenesis. Knowledge of sleep apnea genetics provides not only an opportunity to better understand an individual s predisposition to develop OSA and its neuropsychiatric and cardiovascular consequences but also insight into the molecular pathways that, when dysregulated, produce OSA. The ability to predict individual risk will allow for more efficient prevention and screening programs while knowledge of pathophysiology may allow for novel treatment strategies that specifically target the molecular defects. Sleep Apnea Phenotypes An important consideration in understanding the role of genetics in sleep-disordered breathing is to identify the most relevant phenotype. A feature of OSA shared by many other complex disorders is the lack of a standardized phenotypic definition of disease. OSA is typically defined as the presence of an apnea/hypopnea index (AHI) above a certain threshold (often 45 or 10 events per hour of sleep). Obstructive sleep apnea hypopnea syndrome (OSAHS) represents the combination of OSA with symptoms of sleepiness referable to the OSA. One study found familial aggregation of a phenotype that included symptoms of sleepiness to be greater than phenotypes defined purely on polysomnographic criteria. An important issue is whether heritability is greater for a phenotype based strictly on AHI level or one that uses associated symptoms, such as sleepiness or daytime dysfunction. In addition, the choice of a dichotomous phenotype, such as OSA or OSAHS, versus a continuous phenotype, such as AHI, need also be considered. Although continuous phenotypes typically provide more power for identifying genetic susceptibility loci and do not require arbitrary threshold cutoffs that may vary across subgroups (e.g., children vs. adults), they also make more assumptions regarding scaling (a doubling of AHI from 2 to 4 is of equivalent importance as one from 10 to 20) that may or may not be appropriate.
MODULE. POSITIVE AIRWAY PRESSURE (PAP) Titrations
MODULE POSITIVE AIRWAY PRESSURE (PAP) Titrations POSITIVE AIRWAY PRESSURE (PAP) TITRATIONS OBJECTIVES At the end of this module the student must be able to: Identify the standards of practice for administering
More informationTreatment for Snoring and Obstructive Sleep Apnea. Ri 林 鴻 錡 /AsP 譚 慶 鼎
Treatment for Snoring and Obstructive Sleep Apnea Ri 林 鴻 錡 /AsP 譚 慶 鼎 Nonsurgical treatment Weight loss Avoidance of alcohol,sedatives,tobacco Positional devices Oral or nasal appliances Nasal continuous
More informationROLE OF ORAL APPLIANCES TO TREAT OBSTRUCTIVE SLEEP APNEA
1 ROLE OF ORAL APPLIANCES TO TREAT OBSTRUCTIVE SLEEP APNEA There are three documented ways to treat obstructive sleep apnea: 1. CPAP device 2. Oral Appliances 3. Surgical correction of nasal and oral obstructions
More informationObstructive sleep apnea and type 2 diabetes Obstructive Sleep Apnea (OSA) may contribute to or exacerbate type 2 diabetes for some of your patients.
Obstructive sleep apnea and type 2 diabetes Obstructive Sleep Apnea (OSA) may contribute to or exacerbate type 2 diabetes for some of your patients. Prevalence of OSA and diabetes Prevalence of OSA Five
More informationDepartment of Pulmonology, Critical Care and Sleep Medicine, Bolan Medical College, Pakistan
Cronicon OPEN ACCESS PULMONOLOGY AND RESPIRATORY MEDICINE Review Article Sleep Apnea Sanaullah Tareen Department of Pulmonology, Critical Care and Sleep Medicine, Bolan Medical College, Pakistan *Corresponding
More informationChanges in the Evaluation and Treatment of Sleep Apnea
Changes in the Evaluation and Treatment of Sleep Apnea Joseph DellaValla, MD FACP Medical Director Center for Sleep Medicine At Androscoggin Valley Hospital Sleep Related Breathing Problems Obstructive
More informationUnderwriting Sleep Apnea
Underwriting Sleep Apnea Joel Weiner, MD, FLMI April 29, 2014 WAHLU The Northwestern Mutual Life Insurance Company Milwaukee, WI A Brief Survey Before We Get Started The Weiner Sleepiness Scale How likely
More informationHEALTH EVIDENCE REVIEW COMMISSION (HERC) COVERAGE GUIDANCE: DIAGNOSIS OF SLEEP APNEA IN ADULTS DATE: 5/9/2013 HERC COVERAGE GUIDANCE
HEALTH EVIDENCE REVIEW COMMISSION (HERC) COVERAGE GUIDANCE: DIAGNOSIS OF SLEEP APNEA IN ADULTS DATE: 5/9/2013 HERC COVERAGE GUIDANCE The following diagnostic tests for Obstructive Sleep Apnea (OSA) should
More informationPolysomnography in Patients with Obstructive Sleep Apnea. OHTAC Recommendation. Polysomnography in Patients with Obstructive Sleep Apnea
OHTAC Recommendation Polysomnography in Patients with Obstructive Sleep Apnea June 16, 2006 1 The Ontario Health Technology Advisory Committee (OHTAC) met on June 16, 2006 and reviewed a health technology
More informationMedical Information to Support the Decisions of TUECs INTRINSIC SLEEP DISORDERS
Introduction Excessive daytime sleepiness (EDS) is a common complaint. Causes of EDS are numerous and include: o Intrinsic sleep disorders (e.g. narcolepsy, obstructive sleep apnoea/hypopnea syndrome (OSAHS)
More informationDiseases and Health Conditions that can Lead to Daytime Sleepiness
October 21, 2014 Diseases and Health Conditions that can Lead to Daytime Sleepiness Indira Gurubhagavatula, MD, MPH Associate Professor Director, Occupational Sleep Medicine University of Pennsylvania,
More informationArlington Dental Associates Ira Stier DDS PC 876 Dutchess Tpk 2 Lafayette Ct. Poughkeepsie, NY 12603 Fishkill, NY 12524 845-454-7023 845-896-4977
Home Sleep Test Liability Form Study Equipment Due: @ I, accept responsibility for the sleep monitoring device while it is in rny possession. I understand that if I fail to return the device or I return
More informationPulmonary Diseases. Lung Disease: Pathophysiology, Medical and Exercise Programming. Overview of Pathophysiology
Lung Disease: Pathophysiology, Medical and Exercise Programming Overview of Pathophysiology Ventilatory Impairments Increased airway resistance Reduced compliance Increased work of breathing Ventilatory
More informationPAP Therapy Devices: Delivering the Right Therapy To The Right Patient. Ryan Schmidt, BS,RRT Clinical Specialist Philips Respironics
PAP Therapy Devices: Delivering the Right Therapy To The Right Patient Ryan Schmidt, BS,RRT Clinical Specialist Philips Respironics Conflict of Interest Disclosure(s) I do not have any potential conflicts
More informationDiagnosis and Treatment
Sleep Apnea: Diagnosis and Treatment Sleep Apnea Sleep Apnea is Common Dangerous Easily recognized Treatable Types of Sleep Disordered Breathing Apnea Cessation of airflow > 10 seconds Hypopnea Decreased
More informationSleep Difficulties. Insomnia. By Thomas Freedom, MD and Johan Samanta, MD
Sleep Difficulties By Thomas Freedom, MD and Johan Samanta, MD For most people, night is a time of rest and renewal; however, for many people with Parkinson s disease nighttime is a struggle to get the
More informationSnoring and Obstructive Sleep Apnea (updated 09/06)
Snoring and Obstructive Sleep Apnea (updated 09/06) 1. Define: apnea, hypopnea, RDI, obstructive sleep apnea, central sleep apnea and upper airway resistance syndrome. BG 2. What are the criteria for mild,
More informationNUVIGIL (armodafinil) oral tablet
NUVIGIL (armodafinil) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationRapid Resolution of Intense Suicidal Ideation after Treatment of Severe. From the Department of Psychiatry and Psychology (L.E.K.
Category [Case Report] Rapid Resolution of Intense Suicidal Ideation after Treatment of Severe Obstructive Sleep Apnea Lois E. Krahn, MD Bernard W. Miller, RPSGT Larry R. Bergstrom, MD From the Department
More informationATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)
ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) By Prof. Dr. Helmy A. Bakr Mansoura Universirty 2014 AF Classification: Mechanisms of AF : Selected Risk Factors and Biomarkers for AF: WHY AF? 1. Atrial fibrillation
More informationRaising Sleep Apnea Awareness:
Raising Sleep Apnea Awareness: Among People with Diabetes in North Carolina, 2012 People with diabetes have more sleep problems than people without diabetes in the same age, sex, and race/ethnicity group.
More informationOUTCOMES OF CPAP TREATMENT IN A SLEEP LABORATORY SPECIALIZED IN NEUROPSYCHIATRY
JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 2004, 55, Suppl 3, 15 22 www.jpp.krakow.pl J. ANTCZAK 1,2, P. GEISLER 2, R. POPP 2 OUTCOMES OF CPAP TREATMENT IN A SLEEP LABORATORY SPECIALIZED IN NEUROPSYCHIATRY
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationTreatments for Major Depression. Drug Treatments The two (2) classes of drugs that are typical antidepressants are:
Treatments for Major Depression Drug Treatments The two (2) classes of drugs that are typical antidepressants are: 1. 2. These 2 classes of drugs increase the amount of monoamine neurotransmitters through
More informationObstructive Sleep Apnea (Not so) Sweet Dreams
Obstructive Sleep Apnea (Not so) Sweet Dreams Sleep, riches, and health, to be truly enjoyed, must be interrupted. -- Jean-Paul Richter Presented by: Brad Heltemes, M.D. VP & Chief Medical Director ING
More informationMaharashtra University of Health Sciences, Nashik. Syllabus. Fellowship Course in Sleep Medicine
Maharashtra University of Health Sciences, Nashik Syllabus Fellowship Course in Sleep Medicine Appendix A a) Title of the Fellowship Course: Fellowship Course in Sleep Medicine b) Duration of Course: 1
More informationChildren Who Snore Do they have Sleep Apnea? Iman Sami, M.D. Division of Pulmonary and Sleep Medicine, Children s National
Children Who Snore Do they have Sleep Apnea? Iman Sami, M.D. Division of Pulmonary and Sleep Medicine, Children s National June 3, 2015 No disclosures relevant to this talk No disclosures relevant to this
More informationSLEEP DISORDERS IN ASBESTOS-RELATED DISEASES
SLEEP DISORDERS IN ASBESTOS-RELATED DISEASES Asbestos pleural diseases ie benign asbestos pleural plaques, diffuse pleural thickening, benign asbestos pleurisy, benign asbestos pleural effusions and asbestosis
More informationelf-awareness Toolkit
S Snoring & Sleep Apnea elf-awareness Toolkit Snoring: Your Dentist Can Test So You Can Rest 2009 Snoring Isn t Sexy, LLC S Snoring & Sleep Apnea elf-awareness Toolkit Snoring: Your Dentist Can Test So
More information1. According to recent US national estimates, which of the following substances is associated
1 Chapter 36. Substance-Related, Self-Assessment Questions 1. According to recent US national estimates, which of the following substances is associated with the highest incidence of new drug initiates
More information5.07.04. Provigil Nuvigil. Provigil (modafinil) / Nuvigil (armodafinil) Description. Section: Prescription Drugs Effective Date: July 1, 2015
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.04 Subject: Provigil Nuvigil Page: 1 of 6 Last Review Date: June 19, 2015 Provigil Nuvigil Description
More informationAbout Sleep Apnea ABOUT SLEEP APNEA
ABOUT SLEEP APNEA About Sleep Apnea What is Sleep Apnea? Sleep Apnea (from Greek, meaning "without breath") is one of the most common sleep disorders in which breathing stops and then restarts again recurrently
More informationCPAP Treats Muscle Cramps in Patients with Obstructive Sleep Apnea
CPAP Treats Muscle Cramps in Patients with Obstructive Sleep Apnea Andrew J Westwood, M.D., MRCP(UK) 1, Andrew R Spector, M.D., 2 Sanford H Auerbach, M.D. 3 1 Columbia University College of Physicians
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Remit / Appraisal objective: Final scope To appraise the clinical and cost effectiveness of
More information1. The potential sites of action for sympathomimetics and the difference between a direct and indirect acting agonist.
1 OBI 836 The Autonomic Nervous System-Sympathomimetics M.T. Piascik August 29, 2012 Learning Objectives Lecture II The student should be able to explain or describe 1. The potential sites of action for
More informationOximetry Alone Versus Portable Polygraphy for Sleep Apnea Screening Before Bariatric Surgery
OBES SURG (2010) 20:326 331 DOI 10.1007/s11695-009-0055-9 CLINICAL RESEARCH Oximetry Alone Versus Portable Polygraphy for Sleep Apnea Screening Before Bariatric Surgery Maude Malbois & Vittorio Giusti
More informationHYPERTENSION ASSOCIATED WITH RENAL DISEASES
RENAL DISEASE v Patients with renal insufficiency should be encouraged to reduce dietary salt and protein intake. v Target blood pressure is less than 135-130/85 mmhg. If patients have urinary protein
More informationExecutive Summary. An American Academy of Sleep Medicine and American Academy of Dental Sleep Medicine Clinical Practice Guideline
Executive Summary Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring with Oral Appliance Therapy: An Update for 2015 An American Academy of Sleep Medicine and American
More informationAT HOME DR. D. K. PILLAI MUG @ UOM
NON - INVASIVE VENTILATION AT HOME DR. D. K. PILLAI 07.09.2011 MUG @ UOM In the beginning came. OSA (HS) 1. CPAP for OSAHS (Obstructive Sleep Apnoea Hypopnoea Syndrome) 2 NIPPV 2. NIPPV (Non
More informationDepression is a common biological brain disorder and occurs in 7-12% of all individuals over
Depression is a common biological brain disorder and occurs in 7-12% of all individuals over the age of 65. Specific groups have a much higher rate of depression including the seriously medically ill (20-40%),
More informationMedical Coverage Policy Monitored Anesthesia Care (MAC)
Medical Coverage Policy Monitored Anesthesia Care (MAC) Device/Equipment Drug Medical Surgery Test Other Effective Date: 9/1/2004 Policy Last Updated: 1/8/2013 Prospective review is recommended/required.
More informationTreatment of Obstructive Sleep Apnea (OSA)
MP9239 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below None Prevea360 Health Plan Medical Policy: 1.0 A continuous positive airway
More informationWhat is sleep apnea? 2/2/2010
Outline Nocturia and Sleep Apnea R. Keith Huffaker, MD Introduction Background & Incidence Definitions Differential Diagnosis of Nocturia Risk Factors of OSA Mechanism of OSA-Nocturnal Polyuria Diagnosis
More informationSleep Position Trainer. The best treatment for Positional OSAS
Sleep Position Trainer The best treatment for Positional OSAS Innovation distinguishes between a leader and a follower. - Steve Jobs Positional Therapy for (P)OSAS Positional Obstructive Sleep Apnea Syndrome
More informationMOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines
MOH CLINICL PRCTICE GUIELINES 2/2008 Prescribing of Benzodiazepines College of Family Physicians, Singapore cademy of Medicine, Singapore Executive summary of recommendations etails of recommendations
More informationWhat is Obstructive Sleep Apnoea?
Patient Information Leaflet: Obstructive Sleep Apnoea Greenlane Respiratory Services, Auckland City Hospital & Greenlane Clinical Centre Auckland District Health Board What is Obstructive Sleep Apnoea?
More informationSLEEP AND PARKINSON S DISEASE
A Practical Guide on SLEEP AND PARKINSON S DISEASE MICHAELJFOX.ORG Introduction Many people with Parkinson s disease (PD) have trouble falling asleep or staying asleep at night. Some sleep problems are
More informationObstructive Sleep Apnea and Sleep Disorders in All Age Groups Treatment
Obstructive Sleep Apnea and Sleep Disorders in All Age Groups Treatment W. McD. Anderson, M.D. Medical Director, Tampa General Hospital Sleep Center Professor of Medicine, USF College of Medicine Program
More informationCH CONSCIOUS SEDATION
Summary: CH CONSCIOUS SEDATION It is the policy of Carondelet Health that moderate conscious sedation of patients will be undertaken with appropriate evaluation and monitoring. Effective Date: 9/4/04 Revision
More information2015 Physician Quality Reporting System Data Collection Form: Sleep Apnea (for patients aged 18 and older)
2015 Physician Quality Reporting System Data Collection Form: Sleep Apnea (for patients aged 18 and older) IMPORTANT: Any measure with a 0% performance rate (100% for inverse measures) is not considered
More informationFiberoptic bronchoscopy (FOB) is a procedure that pulmonologists
Original Article Diagnosing Obstructive Sleep Apnea by Performing Fiberoptic Bronchoscopy and PEEP Titration of Mask Continuous Positive Airway Pressure Saenghirunvattana S, MD Sawang Saenghirunvattana,
More informationCPAP titration: PSG technologist or at Home
CPAP titration: PSG technologist or at Home Carolyn D Ambrosio, MD, MS Associate Professor of Medicine Director, The Center for Sleep Medicine Tufts Medical Center Conflict of Interest No financial interest
More informationEXPECTATIONS OF PHYSICIANS INTENDING TO PRACTISE SLEEP MEDICINE CHANGING SCOPE OF PRACTICE PROCESS BACKGROUND
EXPECTATIONS OF PHYSICIANS INTENDING TO PRACTISE SLEEP MEDICINE CHANGING SCOPE OF PRACTICE PROCESS BACKGROUND The College is gradually moving toward a system of performance measurement by focusing on a
More informationChapter 28. Drug Treatment of Parkinson s Disease
Chapter 28 Drug Treatment of Parkinson s Disease 1. Introduction Parkinsonism Tremors hands and head develop involuntary movements when at rest; pin rolling sign (finger and thumb) Muscle rigidity arthritis
More informationPhilip Moore DO, Toxicology Fellow, PinnacleHealth Toxicology Center Joanne Konick-McMahan RN MSRN, Staff RN, PinnacleHealth
Philip Moore DO, Toxicology Fellow, PinnacleHealth Toxicology Center Joanne Konick-McMahan RN MSRN, Staff RN, PinnacleHealth I. II. Background A. AWS can occur in anyone who consumes alcohol B. Risk correlates
More informationSleep Apnea. ACP Oct 26, 2014. Bashir Chaudhary, MD Sleep Institute of Augusta, Augusta GA
Sleep Apnea ACP Oct 26, 2014 Bashir Chaudhary, MD Sleep Institute of Augusta, Augusta GA Emeritus Professor of Medicine and Assistant Dean of Clinical Affairs, CAHS Medical College of Georgia, Georgia
More informationHeadache and Sleep Disorders 屏 東 基 督 教 醫 院 沈 秀 祝
Headache and Sleep Disorders 屏 東 基 督 教 醫 院 沈 秀 祝 Sleep Sleeping later Sleep deprivation Excessive Sleep Sleep Migraine Physiology of sleep Headache Clinical, Anatomical, and Physiologic Relationship Between
More informationInpatient Heart Failure Management: Risks & Benefits
Inpatient Heart Failure Management: Risks & Benefits Dr. Kenneth L. Baughman Professor of Medicine Harvard Medical School Director, Advanced Heart Disease Section Brigham & Women's Hospital Harvard Medical
More informationSeminar/Talk Calendar
Seminar/Talk Calendar Tuesday, February 3rd Dr. John Neumaier, Professor of Psychiatry and Pharmacology, University of Washington DREADDing Addiction Dr. Neumaier s laboratory is studying stress and addiction
More informationPaul Wylie, MD 1, Sukhdev Grover, MD 2 1 Arkansas Center for Sleep Medicine, Little Rock AR; 2 Sleep Center of Greater Pittsburgh, Pittsburgh, PA
Automatic Bi-level Positive Airway Pressure Delivery with Flow-Directed Pressure Modulation and Expiratory Pressure Relief an In-laboratory Comparison with Conventional Bi-level Positive Airway Pressure
More informationCompliance Issues in Home CPAP Therapy. Joseph Lewarski, BS, RRT, FAARC
Compliance Issues in Home CPAP Therapy Joseph Lewarski, BS, RRT, FAARC Obstructive Sleep Apnea Syndrome OSA 1 st recognized over 30 years ago 1981 Sullivan publishes small study in Lancet¹ Late 80s, early
More informationMilwaukee School of Engineering Gerrits@msoe.edu. Case Study: Factors that Affect Blood Pressure Instructor Version
Case Study: Factors that Affect Blood Pressure Instructor Version Goal This activity (case study and its associated questions) is designed to be a student-centered learning activity relating to the factors
More informationRiociguat Clinical Trial Program
Riociguat Clinical Trial Program Riociguat (BAY 63-2521) is an oral agent being investigated as a new approach to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension
More informationUnderstanding Sleep Apnea
Understanding Sleep Apnea www.sleepmangementsolutions.com What is Obstructive Sleep Apnea (OSA)? OSA afflicts 20 million adult men and women in the U.S. People who have OSA stop breathing repeatedly during
More informationComparing the Performance and Efficacy of the 3B/BMC RESmart. Auto-CPAP with the ResMed S9 AutoSet
3B MEDICAL, INC., 21301 US HIGHWAY 27, LAKE WALES, FL. 33859 Comparing the Performance and Efficacy of the 3B/BMC RESmart Auto-CPAP with the ResMed S9 AutoSet Zhi Zhuang, PhD, Research and Development,
More informationDisordered sleep at night has long been
Neurology 59 Excessive daytime sleepiness in PD Excessive Daytime Sleepiness (EDS) in Parkinson s disease (PD) is an important issue that warrants serious attention because it can have adverse effects
More informationUnderstanding Hypoventilation and Its Treatment by Susan Agrawal
www.complexchild.com Understanding Hypoventilation and Its Treatment by Susan Agrawal Most of us have a general understanding of what the term hyperventilation means, since hyperventilation, also called
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationPsychopharmacotherapy for Children and Adolescents
TREATMENT GUIDELINES Psychopharmacotherapy for Children and Adolescents Guideline 7 Psychopharmacotherapy for Children and Adolescents Description There are few controlled trials to guide practitioners
More informationAlcohol Withdrawal. Introduction. Blood Alcohol Concentration. DSM-IV Criteria/Alcohol Abuse. Pharmacologic Effects of Alcohol
Pharmacologic Effects of Alcohol Alcohol Withdrawal Kristi Theobald, Pharm.D., BCPS Therapeutics III Fall 2003 Inhibits glutamate receptor function (NMDA receptor) Inhibits excitatory neurotransmission
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationSection 2. Overview of Obesity, Weight Loss, and Bariatric Surgery
Section 2 Overview of Obesity, Weight Loss, and Bariatric Surgery What is Weight Loss? How does surgery help with weight loss? Short term versus long term weight loss? Conditions Improved with Weight Loss
More informationA Manic Episode is defined by a distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood.
Bipolar disorder Bipolar (manic-depressive illness) is a recurrent mode disorder. The patient may feel stable at baseline level but experience recurrent shifts to an emotional high (mania or hypomania)
More informationObstructive Sleep Apnoea
Obstructive Sleep Apnoea What is obstructive sleep apnoea? People who suffer from Obstructive Sleep Apnoea (OSA) reduce or stop their breathing for short periods while sleeping. This can happen many times
More informationA Healthy Life RETT SYNDROME AND SLEEP. Exercise. Sleep. Diet 1. WHY SLEEP? 4. ARE SLEEP PROBLEMS A COMMON PARENT COMPLAINT?
Diet Sleep Exercise RETT SYNDROME AND SLEEP DR. DANIEL GLAZE, MEDICAL DIRECTOR THE BLUE BIRD CIRCLE RETT CENTER A good night s sleep promotes learning, improved mood, general good health, and a better
More informationSUMMARY OF RECOMMENDATIONS
SUMMARY OF RECOMMENDATIONS FOR THE LONG- TERM TREATMENT OF RLS/WED from AN IRLSSG TASK FORCE Members of the Task Force Diego Garcia- Borreguero, MD, Madrid, Spain* Richard Allen, PhD, Baltimore, MD, USA*
More informationHow To Choose A Biologic Drug
North Carolina Rheumatology Association Position Statements I. Biologic Agents A. Appropriate delivery, handling, storage and administration of biologic agents B. Indications for biologic agents II. III.
More informationEmergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationCardiovascular Risk in Diabetes
Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,
More informationpii: jc-00031-15 http://dx.doi.org/10.5664/jcsm.4556
SPECIAL SECTION pii: jc-00031-15 http://dx.doi.org/10.5664/jcsm.4556 Quality Measures for the Care of Adult Patients with Obstructive Sleep Apnea R. Nisha Aurora, MD 1 ; Nancy A. Collop, MD 2 ; Ofer Jacobowitz,
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationplacebo-controlledcontrolled double-blind, blind,
Clinical Potential of Minocycline for Depression with Psychotic Features Tsuyoshi Miyaoka Department of Psychiatry Shimane University School of Medicine Minocycline 1. Second-generation tetracycline which
More informationLOW T NATION TESTOSTERONE INTAKE FORM NAME: DATE: ADDRESS: CITY: STATE: ZIP: CELL #: HOME #: SOC SECURITY #: DATE OF BIRTH:
LOW T NATION TESTOSTERONE INTAKE FORM NAME: DATE: ADDRESS: CITY: STATE: ZIP: CELL #: HOME #: SOC SECURITY #: DATE OF BIRTH: DRIVERS LICENSE NUMBER: STATE: EMAIL ADDRESS: MARITAL STATUS: ( ) SINGLE ( )
More informationINSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME
1 University of Papua New Guinea School of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PBL SEMINAR INSULIN RESISTANCE, POLYCYSTIC OVARIAN
More informationPHSW Procedural Sedation Post-Test Answer Key. For the following questions, circle the letter of the correct answer(s) or the word true or false.
PHSW Procedural Sedation Post-Test Answer Key 1 1. Define Procedural (Conscious) Sedation: A medically controlled state of depressed consciousness where the patient retains the ability to continuously
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More informationMOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION
MOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION Executive summary of recommendations Details of recommendations can be found in the main text at the pages indicated. Clinical evaluation D The basic
More informationDoes Depression affect compliance with CPAP therapy in patients with Obstructive Sleep Apnea? Ramesh Metta, MBBS M Jeffery Mador, MD
Does Depression affect compliance with CPAP therapy in patients with Obstructive Sleep Apnea? Ramesh Metta, MBBS M Jeffery Mador, MD Background Obstructive Sleep Apnea(OSA) Obstructive sleep apnea (OSA)
More informationSLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS
E-Resource December, 2013 SLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS Between 10-18% of adults in the general population and up to 50% of adults in the primary care setting have difficulty sleeping. Sleep
More informationNursing Interventions for Sleep Disorders Following TBI
Nursing Interventions for Sleep Disorders Following TBI Kadesha Clark, RN BSN When you sleep, your body rests and restores its energy levels. A good night's sleep is often the best way to help you cope
More informationShira Miller, M.D. Los Angeles, CA 310-734-8864 www.shiramillermd.com. The Compounding Pharmacy of Beverly Hills Beverly Hills Public Library
Shira Miller, M.D. Los Angeles, CA 310-734-8864 The Compounding Pharmacy of Beverly Hills Beverly Hills Public Library 2 Outline What is hormone therapy? Why would healthy men and women need to think about
More informationBaskets of Care Diabetes Subcommittee
Baskets of Care Diabetes Subcommittee Disclaimer: This background information is not intended to be a comprehensive scientific discussion of the topic, but rather an attempt to provide a baseline level
More informationOVERACTIVE BLADDER DIAGNOSIS AND TREATMENT OF OVERACTIVE BLADDER IN ADULTS:
2014 OVERACTIVE BLADDER DIAGNOSIS AND TREATMENT OF OVERACTIVE BLADDER IN ADULTS: AUA/SUFU Guideline (2012); Amended (2014) For Primary Care Providers OVERACTIVE BLADDER Diagnosis and Treatment of Overactive
More informationO bstructive sleep apnoea syndrome (OSAS) is a
430 SLEEP DISORDERED BREATHING Continuous positive airway pressure reduces daytime sleepiness in mild to moderate obstructive sleep apnoea: a meta-analysis N S Marshall, M Barnes, N Travier, A J Campbell,
More informationNational MS Society Information Sourcebook www.nationalmssociety.org/sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers
More informationSign up to receive ATOTW weekly - email worldanaesthesia@mac.com
OBSTRUCTIVE SLEEP APNOEA AND ANAESTHESIA ANAESTHESIA TUTORIAL OF THE WEEK 152 21 ST SEPTEMBER 2009 Dr Shona Bright Royal Hobart Hospital Correspondence to shona.bright@dhhs.tas.gov.au QUESTIONS Before
More informationACLS PHARMACOLOGY 2011 Guidelines
ACLS PHARMACOLOGY 2011 Guidelines ADENOSINE Narrow complex tachycardias or wide complex tachycardias that may be supraventricular in nature. It is effective in treating 90% of the reentry arrhythmias.
More information2. Background This drug had not previously been considered by the PBAC.
PUBLIC SUMMARY DOCUMENT Product: Ambrisentan, tablets, 5 mg and 10 mg, Volibris Sponsor: GlaxoSmithKline Australia Pty Ltd Date of PBAC Consideration: July 2009 1. Purpose of Application The submission
More informationSummary of the risk management plan (RMP) for Ofev (nintedanib)
EMA/738120/2014 Summary of the risk management plan (RMP) for Ofev (nintedanib) This is a summary of the risk management plan (RMP) for Ofev, which details the measures to be taken in order to ensure that
More information